SUMMARY From January 1954 to December 1985 cardiac myxoma was diagnosed in 75 patients at the Mayo Clinic. The clinical presentation was typical in 70 cases and was referred to as "sporadic myxoma". Forty four other cases of cardiac myxomas (five from the Mayo Clinic) presented with a combination of distinctive clinical features and these cases are described as "syndrome myxoma". The patients with syndrome myxoma were younger (mean age, 25 vs 56 years) and had unusual skin freckling (68%), associated benign non-cardiac myxomatous tumours (57%), endocrine neoplasms (30%), and a high frequency of familial cardiac myxoma (25%) and familial endocrine tumours (14%). The two types of cardiac tumour were different (syndrome vs sporadic): atrial location, 87% vs 100%; ventricular location, 13% vs 0%; single tumour, 50% vs 99O%; multiple tumours, 50%/ vs 1%; and recurrent tumour, 18% vs 0%.
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It is concluded that patients with syndrome myxoma represent a distinctive subgroup in which there are important clinical, surgical, and genetic implications. More importantly, syndrome myxoma appears to be only one expression of a much larger disease entity. Although it is rare, cardiac myxoma is the most frequently encountered primary neoplasm of the heart.' Cardiac myxomas are typically sporadic, benign, non-recurring, left atrial tumours.1 They are usually attached to the atrial septum, in or about the valve of the fossa ovalis, and are more common in females and in patients aged from 30 to 60. 2 From a review of experience at the Mayo Clinic and a critical review of published reports we recognised a subset of patients with cardiac myxoma and associated systemic manifestations including pigmented skin lesions and non-cardiac tumours.3
These patients have distinctive clinical features that separate them from the larger group of patients with the more common sporadic myxoma. 2 We call the condition in this subset of patients "syndrome myxoma".
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Accepted for publication 13 October 1986 We have compared sporadic myxoma with syndrome myxoma and we summarise the specific findings that allow clinical distinction between the two. The most important distinction is that syndrome myxoma appears to be a multisystem disease. abnormalities and have an autosomal dominant mode of inheritance. Albright's fibrous dysplasia55 and neurofibromatosis56 are associated with hyperpigmented skin lesions, endocrine abnormalities, and soft tissue myxomas. Unlike most of these similar conditions, which are the result of a mutation in the embryonic neural crest,56 57 myxomas are believed to be of mysenchymal origin. A recent report, however, suggests the possibility of maldevelopment of the neural crest in cardiac myxoma. 58 We have avoided the use of mnemonic acronyms such as NAME5 (N = naevi, A = atrial myxoma, M = mucocutaneous myxomas, E = ephelides) or LAMB28 (L = lentigines, A = atrial myxoma, M = mucocutaneous myxomas, B = blue naevi) to describe the features of syndrome myxoma. Such acronyms describe only some of the manifestations of the syndrome, which appears to be a multisystem condition that may be associated with cardiac myxoma. We therefore believe there is no suitable acronym.
Patients and methods
In summary, syndrome myxoma should be suspected in any patient under age 40 years with a cardiac myxoma at a site other than the left atrium. Such patients should be assessed preoperatively for important associations including adrenal integrity, and the surgeon should be made aware of the need for thorough inspection of the heart for multiple subclinical myxomas. Any patient who has familial, recurrent, ventricular, or multiple cardiac myxomas and is unusually freckled or has peripheral noncardiac myxomas or a rare endocrine neoplasm should be followed because syndrome myxoma often recurs. If syndrome myxoma is recognised in an individual, all the first degree relatives should undergo formal evaluation. Cardiac myxoma appears to be only one of the many manifestations of syndrome myxoma.
